IG
CYTK icon

ING Group’s Cytokinetics CYTK Stock Holding History

ING Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-423,232
Closed -$2.75M – 697
2013
Q4 		$2.75M Hold
423,232
– – 0.01% 427
2013
Q3 		$3.21M Buy
+423,232
New +$4.54M 0.02% 444

Other funds holding CYTK

LPLP
Lansdowne Partners Limited Partnership London, United Kingdom $11.9B AUM 36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

ING Group's CYTK Position: Q1 2014 in Review

ING Group sold out of Cytokinetics (CYTK) in Q1 2014, closing a stake of 423,232 shares — an estimated $2.75M sold.

ING Group first reported a position in CYTK in Q3 2013 and held it in 2 quarters. The position peaked at $3.21M in Q3 2013. 109 funds tracked by Wall St. Rank hold CYTK as of Q1 2014.

  • ING Group reported no remaining Cytokinetics position as of Q1 2014 after selling out during the quarter.
  • ING Group sold 423,232 Cytokinetics shares in Q1 2014, an estimated $2.75M.
  • ING Group first reported a position in Cytokinetics in Q3 2013 and held it in 2 quarters.
  • ING Group's Cytokinetics position peaked at $3.21M in Q3 2013.
  • 109 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2014.

Based on ING Group's 13F filing for Q1 2014, filed 14 May 2014.